When a medication or implant intended to heal instead causes harm, the path to accountability is technical, evidence-heavy, and time-sensitive. For Indiana patients and families, local experience matters because product cases turn on state-specific rules and federal safety standards. Cohen & Malad, LLP helps clients navigate this terrain by assembling the right experts, contextualizing FDA records, and building a narrative that links defect to injury. As Indianapolis Drug & Medical Device lawsuits evolve, evidence sources—from electronic health records to device registries—grow more sophisticated. This article explains how attorneys map the legal elements, interpret current FDA oversight, and pursue compensation strategies tailored to long-term health impacts.
Understanding product liability in defective drug and device claims
Product liability in pharmaceutical and device litigation hinges on proving a defect and tying that defect to a plaintiff’s injuries. The primary theories—design defect, manufacturing defect, and failure to warn—apply differently depending on whether the product is a prescription drug, a Class III implanted device, or a generic formulation. Indiana’s Product Liability Act shapes many of these claims, while federal preemption can narrow or expand the path forward based on the product’s regulatory status. For example, branded drug manufacturers may face claims that their labeling should have been updated to reflect known risks, whereas generic manufacturers benefit from stronger labeling preemption. Attorneys must reconcile these overlapping legal regimes with a clear causation story rooted in medical records, prescribing decisions, and adverse event data.
Frameworks that shape liability analysis
Attorneys start by identifying the defect category and matching it to the governing legal standard. In a design defect theory, evidence often focuses on alternative designs, comparative risk-benefit, and whether reasonable testing would have revealed the danger before market entry. Manufacturing defect claims look for deviations from specifications, such as a contaminated lot, improper sterilization, or miscalibrated production processes that make a particular unit dangerous. For failure to warn, practitioners evaluate the label’s content, post-market signals, and the “learned intermediary” doctrine, which measures what risks were communicated to the prescribing clinician. Skilled counsel weave these threads together to explain why a warning was inadequate, why an alternative design was feasible, or why production controls fell short—always linking that shortfall to the plaintiff’s specific injury.
Preemption considerations further refine the strategy. Devices approved through premarket approval (PMA) processes often raise Riegel-based preemption issues, meaning only claims “parallel” to federal requirements may proceed. Branded drugs are analyzed under Wyeth-style reasoning about the duty to strengthen warnings when new risk information emerges, whereas Mensing and Bartlett decisions may limit claims against generic drug makers. Physicians’ clinical decision-making, informed consent notes, and medical literature help establish what risks were known or knowable at the time of use. Seasoned litigators assemble this mosaic so that jurors and judges can see not just a defect in the abstract, but a direct, medically grounded connection to the harm endured in Indianapolis Drug & Medical Device cases.
Recent FDA oversight trends affecting 2025 litigation
The FDA’s post-market vigilance continues to shape discovery and liability theories as we move through 2025 litigation windows. Enhanced use of real-world evidence programs, more rigorous post-market surveillance orders for high-risk devices, and maturing unique device identification (UDI) systems mean attorneys have greater access to traceability data. For drugs, REMS updates, safety communications, and labeling change histories serve as timelines showing what the manufacturer knew and when action was reasonable or required. Device cybersecurity submissions, which the agency began scrutinizing more closely, now influence whether a manufacturer adequately managed foreseeable digital risks. These developments make it increasingly difficult for companies to argue that red flags were invisible or that corrective measures were impractical.
What the oversight emphasis means for plaintiffs
Lawyers leverage FDA databases—FAERS for drugs and MAUDE for devices—together with 522 post-market study reports, recall classifications, and warning letters to build a chronology of risk. When an attorney can demonstrate that adverse signals accumulated while warnings stayed static—or that field corrections were piecemeal and late—the argument for failure to warn or negligent post-market surveillance gains traction. Cybersecurity is emerging as a concrete liability arena for connected devices, where vulnerabilities can translate to delayed therapy, device malfunction, or patient data risks. Attorneys also examine whether manufacturers complied with human factors guidance and whether instructions for use realistically accounted for clinician workflow. For Indianapolis Drug & Medical Device claims, these oversight trails help anchor expert opinions in documented regulatory facts, strengthening causation and fault.
Moreover, the interplay between FDA actions and civil discovery is expanding the evidentiary record. eSTAR submissions, De Novo decisions, and 510(k) summaries provide insight into design rationales and known hazard mitigations. When recalls coincide with internal corrective and preventive action (CAPA) files, discovery can surface root causes that map directly to plaintiffs’ injuries. As oversight trends push transparency forward, the evidentiary burden remains rigorous but more navigable for firms experienced in pharmaceutical and device litigation. Cohen & Malad, LLP integrates these regulatory materials with clinical data, ensuring courts see a comprehensive picture rather than isolated snippets.
How attorneys prove negligence and manufacturer fault
Proving negligence in a drug or device case requires meticulous alignment of medical facts, regulatory compliance data, and corporate decision-making. The core elements—duty, breach, causation, and damages—are built from medical records, prescriber testimony, adverse event patterns, and internal documents unearthed through discovery. Attorneys scrutinize design history files, complaint handling logs, and risk analyses to show that known hazards were downplayed or inadequately mitigated. Prescriber depositions help address the learned intermediary doctrine by exploring whether different warnings would have changed the clinical decision. The goal is to move beyond general criticisms and pinpoint specific conduct that made the product unreasonably dangerous at the time of use.
From investigation to courtroom narrative
The investigative phase begins with preserving physical evidence, gathering pharmacy and surgical records, and confirming lot or serial numbers that tie a product to broader defect patterns. Counsel frequently seek testing of exemplars or the actual device—especially with explanted components—to uncover manufacturing anomalies or wear patterns inconsistent with safe design. Expert witnesses then translate technical flaws into clear explanations of how the product’s properties interacted with human physiology to cause harm. Attorneys also map a precise medical timeline: initial exposure or implantation, onset of symptoms, diagnostic findings, and any corrective procedures, creating the backbone of causation. This step-by-step approach allows jurors to see how discrete corporate choices, not mere bad luck, produced the injury.
Discovery sharpens these themes. Requests target emails about risk signals, harm-benefit assessments, labeling committee minutes, and post-market surveillance protocols, often revealing whether a delay in action was motivated by caution or market considerations. When patterns show repeated complaints with slow corrective responses, negligence claims gain credibility. For Indianapolis Drug & Medical Device litigation, the combination of local medical testimony and national regulatory evidence is especially powerful, situating the plaintiff’s experience within a documented trend. With coordinated strategy, Cohen & Malad, LLP crafts a compelling narrative that presents fault as the inevitable endpoint of avoidable decisions.
The role of expert witnesses and medical documentation
Expert witnesses are the bridge between complex science and legal standards, translating technical details into accessible, courtroom-ready testimony. Pharmacologists, toxicologists, biomedical engineers, and human factors specialists each answer distinct questions about how a product should perform and why it failed. Regulatory experts contextualize FDA filings and post-market actions, helping jurors understand what a reasonable manufacturer would do as risks evolve. Equally critical are treating physicians, whose clinical perspective grounds the case in individual medical reality rather than theoretical hazard. Under Indiana’s Rule 702 and Daubert principles, admissibility turns on reliable methodology, which means experts must connect their opinions to robust data and accepted scientific practice.
Building a record that survives Daubert challenges
Medical documentation forms the backbone of causation and damages proof. Comprehensive EHRs, pharmacy dispensing logs, informed consent forms, and operative reports frame exposure, risk communication, and injury progression. For devices, surgical notes, imaging, and pathology assessments of explanted components can reveal design defect markers or premature wear inconsistent with intended use. Drug cases rely on dose histories, lab results, and differential diagnosis to rule out alternative causes and substantiate the causal chain. The stronger this medical record, the more resilient expert opinions become when challenged.
Experts synthesize these records with regulatory and engineering evidence. A biomedical engineer may align stress analysis of a fractured component with manufacturing tolerances, while a pharmacologist explains how a label’s omission of a specific interaction may have precipitated an adverse event. When opinions are tightly moored to peer-reviewed literature, device registries, and FDA adverse event data, courts are more likely to find the methodology reliable. In Indianapolis Drug & Medical Device cases, local hospital protocols and clinician testimony further corroborate how the product was actually used in practice. By orchestrating this interplay of science and documentation, Cohen & Malad, LLP ensures the case is both technically sound and narratively persuasive.
Compensation recovery strategies for long-term health damages
Recovery in defective product cases must account for both immediate losses and the cascading impact of chronic conditions. Economic damages typically include past and future medical expenses, lost wages, and diminished earning capacity, while non-economic damages address pain, suffering, and loss of normal life. For patients living with permanent complications—revision surgeries, organ damage, or neurological deficits—attorneys develop life care plans that detail decades of anticipated costs. Present value analysis, vocational assessments, and home modification estimates transform medical narratives into quantifiable losses. Because statutes of limitation and repose can be unforgiving, early action preserves claims and critical evidence needed to establish the full scope of harm.
Turning proof into sustainable outcomes
A successful damages case pairs expert testimony with careful lien resolution and structured settlements when appropriate. Life care planners and economists translate clinical trajectories into budgets that jurors can understand, while also accommodating uncertainty through ranges and contingencies. Medicare, Medicaid, and ERISA lienholders must be addressed strategically to protect net recovery, particularly in cases involving long-term therapy or durable medical equipment. In multidistrict litigation or coordinated proceedings, attorneys balance global settlement opportunities with individualized proof, ensuring clients with severe injuries are not undervalued. These tactics are especially important in Indianapolis Drug & Medical Device litigation, where local costs of care and access to specialist services influence lifetime projections.
Ultimately, the pathway to meaningful compensation is built on clarity: clear causation, clear evidence of fault, and a clear picture of future needs. Attorneys marshal treating physicians, rehabilitation specialists, and economists to demonstrate why a particular award is necessary to sustain health and dignity over time. When punitive damages are available, evidence of reckless disregard—such as ignored adverse signals or suppressed safety data—can reinforce accountability aims beyond individual compensation. By aligning damages strategy with the strengths of the liability and medical proof, Cohen & Malad, LLP helps clients secure resources that match the realities of living with a defective drug or device injury. For families navigating these cases, a disciplined approach to evidence and valuation can be the difference between a short-term settlement and a durable solution.
